Healthy pregnancy hub

Amlodipine (Norvasc®)

Last Update: 16 Oct 2025

Welcome to our fact sheet on amlodipine during pregnancy and breastfeeding or chestfeeding. This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.

The HEALTHY PREGNANCY HUB team is collaborating with MotherToBaby to share information on this topic. The original version is available here (August 2024).

Serene, our chatbot, can also answer your questions about medications during pregnancy.

Please note that this fact sheet is based on United States information and has been adapted for Canada, with a review by our Canadian experts. Minor differences may exist between the two countries. Always consult your healthcare professional for information tailored to your situation.

1. What is amlodipine?

Amlodipine is a medication that has been used to treat high blood pressure (hypertension). It is in a class of medications called calcium channel blockers. A brand name for amlodipine is Norvasc®. 

Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy. 

People who are pregnant and have high blood pressure have a greater chance of developing pre-eclampsia (high blood pressure and problems with organs, such as the kidneys or the heart) that can lead to seizures (called eclampsia). High blood pressure can increase the chance for medical complications for the person who is pregnant and for the pregnancy. 

2. What does research say about the risks during pregnancy?

I take amlodipine. Can it make it harder for me to get pregnant?

Studies have not been done to see if amlodipine can make it harder to get pregnant. 

Does taking amlodipine increase the chance of miscarriage?

Miscarriage is common and can occur in any pregnancy for many different reasons. Studies have not been done to see if amlodipine can increase the chance of miscarriage. One study looking at 78 pregnant persons who took calcium channel blockers did not find a higher chance of miscarriage. 

Does taking amlodipine increase the chance of birth defects?

Birth defects can happen in any pregnancy for different reasons. Out of all babies born each year, about 3 out of 100 (3%) will have a birth defect. Information on the use of amlodipine in pregnancy is very limited. Most available information on the use of calcium channel blockers as a group in human pregnancy does not suggest an increased chance of birth defects. 

Does taking amlodipine in pregnancy increase the chance of other pregnancy-related problems?

There are very few studies on the use of amlodipine during pregnancy. One study comparing amlodipine to nifedipine (a similar medication) found no difference in the chance of other pregnancy related problems, including need for a c-section section, preterm delivery (birth before week 37), placental abruption (when the placenta pulls away from the wall of the uterus before labor starts), or growth restriction (babies that are smaller than usual). Available data on the use of calcium channel blockers as a group does not suggest an increased chance of pregnancy complications. 

Uncontrolled high blood pressure during pregnancy has been associated with growth restriction and a higher chance of preterm delivery. 

Does taking amlodipine in pregnancy affect future behavior or learning for the child?

Studies have not been done to see if amlodipine can increase the chance of behavior or learning issues for the child. 

3. Breastfeeding​/ chestfeeding​ while taking amlodipine

Information on the use of amlodipine in breastfeeding/ chestfeeding is limited. The amount of amlodipine in milk is usually low and side effects in nursed infants have not been reported. 

The product label for amlodipine recommends people who are breastfeeding/ chestfeeding to not use this medication. But, the benefits of using amlodipine and the benefits of breastfeeding/ chestfeeding your baby might outweigh possible risks. Your healthcare providers can talk with you about using amlodipine and what treatment is best for you. Be sure to talk to your healthcare provider about all your breastfeeding or chestfeeding questions. 

4. What about fathers and sperm donors?

If a male takes amlodipine, could it affect fertility or increase the chance of birth defects?

Studies have not been done to see if amlodipine could affect a male’s fertility (ability to get a person pregnant) or increase the chance of birth defects above the background risk. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures here.

Key points

  • Amlodipine is a medication used to treat high blood pressure, and it belongs to a group called calcium channel blockers. 
  • Current research does not show a higher risk of birth defects or pregnancy complications when amlodipine is used. 
  • Uncontrolled high blood pressure during pregnancy can lead to growth problems for the baby and increase the risk of preterm birth. 
  • No side effects have been reported in breastfed or chestfed babies, and the amount of medication in milk appears to be low. 
  • There are no studies on amlodipine’s effects on male fertility, but exposures from the male side are unlikely to increase pregnancy risks. 
  • Always talk to your healthcare provider before making any changes to your medication during pregnancy or breastfeeding/ chestfeeding.

References

Please click here for references. 

URL copied!

Disclaimer

HEALTHY PREGNANCY HUB provides a source of information validated by health professionals; however, this information is provided for informational purposes only and should not replace professional advice. Medical standards and practices evolve as new data becomes available, so it is imperative to consult your doctor or a qualified health professional for any questions or concerns regarding your health without delay or omission. It is the responsibility of your treating physician or any other health professional, based on their independent experience and knowledge of the patient, to determine the best way to evaluate and treat you.

HEALTHY PREGNANCY HUB does not specifically recommend or endorse any test, practitioner, treatment, product, or opinion mentioned on our platform. HEALTHY PREGNANCY HUB also does not replace the individual patient assessment based on the examination by the healthcare provider of each patient and the consideration of laboratory data and other patient-specific factors.

The use of the information available on our site is at your own risk. No person involved in the creation, production, promotion, or marketing of HEALTHY PREGNANCY HUB guarantees or represents, expressly or implicitly, anything regarding the information available on the platform, which is provided “as it is”. All warranties are expressly excluded and disclaimed, including but not limited to implied warranties of merchantability or fitness for a particular purpose, as well as any warranties arising by law or otherwise in law or from trade or usage. Any statements or representations made by any other person or entity are void.

While consulting symptoms or other medical information on our platform may guide your discussions with your healthcare professional, this information should not be used to make a medical diagnosis or determine treatment. Before making changes to your supplement or medication regimen, please discuss with your medical team or contact 811 (Canada) to ensure the relevance of these changes to your individual situation.

Credits
MotherToBaby
Organization of Teratology Information Specialists (OTIS)
View source
Evelyne Rey
CHU Sainte-Justine
Modupe Tunde-Byass
University of Toronto
Enav Zusman
The University of British Columbia
R. Douglas Wilson
University of Calgary
Judith Cottin
Émy Roberge
Centre hospitalier universitaire Sainte-Justine
Folasade Elizabeth Olaniyan

Associated Fact Sheets

You want to know more about this topis? Discover our associated Fact Sheets!

Associated Resources

Want to know more? Discover our other contents associated to the topic.

Our interactive tools

Ask your questions and receive help from our personalized AI.

Try it now!

Explore our reading assistance tool.

Test them out today!

Partners

Your pregnancy during COVID-19
uOttawa
University of Calgary
University of British Columbia
University of Saskatchewan
University of Manitoba
University of Alberta
Unité de soutien SSA
UDEM
Stratos
SOGC
RQRM
QTNPR
QPC
PWHR
Public Health Agency of Canada
PregMed France
SPOR
MPrint
Mitacs
Médicaments Grossesse
McGill
Médicament Québec
FRQ
Perinatal Network
CIHR
IQVIA
iPOP
Institut national de santé publique du Québec
INRS
Innovative Medicines Canada
IN-uTERO
Immerscience
Groww
Enrich
Design Develop Discover
CUSM
CIHR
CHU Sainte-Justine
Centre of Excellence on Partnership with Patients and the Public
CAN-AIM
Canadian Pharmacogenomics Network for Drug Safetry
CAMCCO
CAMCCO-L
C4T
BORN Ontario
Black Physicians of Canada
BC Children's Hospital
Alberta Health Services
MICYRN
UQAT
Dalhousie University